Comparison of In vivo toxicity and anti-glatiramer acetate IgG antibody titers in rats Treated with glatiramer acetate (Copaxone) and follow-on glatiramer acetate (FOGA) products

被引：0
|
作者：
Konya, A. [1 ]
Timan, B. [2 ]
Ashkenazi, N. [2 ]
Bursztyn, D. [2 ]
Gyure, L. [1 ]
Vardi, M. [2 ]
Alexander, J. [3 ]
Loupe, P. [4 ]
Nock, S. [5 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Debrecen, Hungary
[2] Teva Pharmaceut Ind Ltd, Netanya, Israel
[3] Teva Pharmaceut Ind Ltd, Denver, CO USA
[4] Teva Pharmaceut Ind Ltd, Overland Pk, KS USA
[5] Teva Pharmaceut Ind Ltd, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P678
引用
收藏
页码：337 / 337
页数：1
相关论文
共 43 条
  • [31] !Hass J, !Firzlaff M (2005).: Twenty-four-month comparison of immunomodulatory treatments -: a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)
    Hasford, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (11) : 916 - 917
  • [32] Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study
    Zivadinov, Robert
    Hojnacki, David
    Hussein, Sara
    Bergsland, Niels
    Carl, Ellen
    Durfee, Jacqueline
    Dwyer, Michael G.
    Kennedy, Cheryl
    Weinstock-Guttman, Bianca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (05) : 5659 - 5673
  • [33] !Hass J, !Firzlaff M (2005).: Twenty-four-month comparison of immunomodulatory treatments -: a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®) -: Reply
    Haas, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (11) : 917 - 917
  • [34] Drop outs analysis: 10 years follow-up in a cohort of rellapsing-remitting multiple sclerosis patients in Argentina treated with interferons or glatiramer acetate
    Carra, A.
    Onaha, P.
    Luetic, G.
    Burgos, M.
    Crespo, E.
    Halfon, J.
    Lopez, A.
    Sinay, V.
    Vrech, C.
    MULTIPLE SCLEROSIS, 2006, 12 : S84 - S84
  • [35] Comparison of efficacy between glatiramer acetate and interferon b-1b in multiple sclerosis patients (MSpts): A two-year follow up study
    Flechter, S
    Vardi, J
    Rabey, JM
    NEUROLOGY, 1999, 52 (06) : A497 - A497
  • [36] A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients
    Avila, Sandra
    De Jesus Guerrero-Garcia, Jose
    Becerril-Villanueva, Enrique
    Perez-Sanchez, Gilberto
    Pavon, Lenin
    Rojas-Mayorquin, Argelia E.
    Alberto Mireles-Ramirez, Mario
    Francisco Munoz-Vallee, Jose
    Vallejo-Castillo, Luis
    Medina-Rivero, Emilio
    Ortuno-Sahagun, Daniel
    Mayra Perez-Tapia, Sonia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 34 : 92 - 99
  • [37] Cognitive and affective 24-month follow-up of multiple sclerosis patients treated with glatiramer acetate or interferon-β: the "Immunomodulating Treatments Affective and Cognitive Aspects'' (ITACA) study
    Canale, S.
    Falautano, M.
    Martinelli, V.
    Di Serio, C.
    Moiola, L.
    Radaelli, M.
    Leopizzi, E.
    Orsi, C.
    Comi, G.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S228 - S228
  • [38] ITACA Study: final data. Cognitive and affective 24-month follow-up of multiple sclerosis patients treated with glatiramer acetate or β-interferon: the 'immunomodulating treatments affective and cognitive aspects'
    Canale, S.
    Falautano, M.
    Martinelli, V.
    Solari, A.
    Mattioli, F.
    Amato, M. P.
    Simone, I.
    Pozzilli, C.
    Patti, F.
    Di Serio, C.
    Radaelli, M.
    Leopizzi, E.
    Comi, G.
    JOURNAL OF NEUROLOGY, 2010, 257 : S188 - S188
  • [39] Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
    Rovaris, M.
    Comi, G.
    Rocca, M. A.
    Valsasina, P.
    Ladkani, D.
    Pieri, E.
    Weiss, S.
    Shifroni, G.
    Wolinsk, J. S.
    Filippi, M.
    MULTIPLE SCLEROSIS, 2007, 13 (04): : 502 - 508
  • [40] Tracking in vivo immune modulation in MS patients treated with glatiramer acetate (GA) alone, or with GA preceded by mitoxantrone, provides novel insights into the mode of action of therapeutic strategies that combine immune suppression and immune deviation
    Bar-Or, Amit
    Gibbs, Ebrima
    Niino, Masaaki
    Alatab, Sudabeh
    Shi, Fu Dong
    Campagnolo, Denise
    Jalili, Farzaneh
    Rhodes, Susan
    Yamashita, Tami
    Fan, Boli
    Freedman, Mark
    Panitch, Hillel
    Arnold, Douglas
    Vollmer, Timothy
    Oger, Joel
    NEUROLOGY, 2007, 68 (12) : A18 - A18
12345